Home | Lymphoma Hub
Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease
Related Articles
Study Finds Unique Pattern of Blood Clots in Sickle Cell Trait but Low Overall Clot Risk – Hematology.org
Study Finds Unique Pattern of Blood Clots in Sickle Cell Trait but Low Overall Clot Risk
IASLC Global Survey on Biomarker Testing Reveals Progress and Persistent Barriers in Lung Cancer Biomarker Testing
Despite significant improvements in the perception of biomarker testing, substantial barriers to implementation may persist globally, according to findings presented at the International Association f…
Telehealth speeds access to clinical trials for cancer
Physicians @OSUCCC_James are pioneering telehealth to give more patients access to lifesaving clinical trials.
Do young patients benefit from immune checkpoint inhibitors?
Efficacy of anti-PD-1 agents in children, adolescents and young adults with melanoma prompts the call for a change in cancer care for this population
Effect of Adding Electroacupuncture to Standard Triple Antiemetic Therapy on Chemotherapy-Induced Nausea and Vomiting: A Randomized Controlled Clinical Trial | Journal of Clinical Oncology
PURPOSE We aim to determine the effectiveness of adding electroacupuncture to standard triple antiemetic therapy for treating chemotherapy-induced nausea and vomiting (CINV). METHODS From March…
N-803 May Overcome ICI Resistance in NSCLC
Adding nogapendekin alfa inbakicept-pmln (N-803) to immune checkpoint inhibitor (ICI) therapy may overcome ICI resistance in patients with NSCLC.
FDA Grants Orphan Drug Designation to Tebapivat for MDS
The FDA has granted orphan drug designation to tebapivat for the treatment of myelodysplastic syndromes.
Risk of Incident Melanoma Among Individuals With Low-Count Monoclonal B-Cell Lymphocytosis | Journal of Clinical Oncology
PURPOSE Chronic lymphocytic leukemia (CLL)-phenotype monoclonal B-cell lymphocytosis (MBL) is a premalignant condition that is roughly 500-fold more common than CLL. It is unknown whether…
Frontline Golcadomide/R-CHOP Shows Potent Antitumor Activity in Aggressive B-Cell Lymphoma
Golcadomide plus R-CHOP was well tolerated and demonstrated high metabolic response rates that were durable in patients with previously untreated a-BCL.
A boost for poor graft function
In this issue of Blood Advances, Shapiro etĀ al1 report the results of a retrospective study evaluating the use of a CD34+ selected stem cell boost…
